Preclinical studies demonstrated that tipifarnib disrupts HRAS membrane localization and signaling, leading to tumor regression in HRAS-mutant HNSCC models, with efficacy tightly dependent on HRAS mutation status [74]. The gene discussed is HRAS; the disease is neoplasm.